Therapeutic vaccine targeting dual immune checkpoints induces potent multifunctional CD8⁺ T cell anti-tumor immunity

Vaccines targeting immune checkpoints represent a promising immunotherapeutic approach for solid tumors. However, the therapeutic efficacy of dual targeting immune checkpoints is still unclear in renal carcinoma.

An adenovirus (Ad) vaccine targeting B7H1 and B7H3 was developed and evaluated for its therapeutic efficacy in subcutaneous, lung metastasis or orthotopic renal carcinoma mouse and humanized models using flow cytometry, Enzyme-linked immunosorbent spot (ELISPOT), cytotoxic T lymphocyte (CTL) killing, cell deletion, hematoxylin and eosin (HE) staining, and immunohistochemistry (IHC) assays.

The Ad-B7H1/B7H3 immunization effectively inhibited tumor growth and increased the induction and percentages of CD8⁺ T cells in subcutaneous tumor models. The vaccine enhanced the induction and maturation of CD11c⁺ or CD8⁺CD11c⁺ cells, promoting tumor-specific CD8⁺ T cell immune responses. This was evidenced by increased proliferation of CD8⁺ T cells and enhanced CTL killing activity. Deletion of CD8⁺ T cells in vivo abolished the anti-tumor effect of the Ad-B7H1/B7H3 vaccine, highlighting the pivotal role of functional CD8⁺ T cell immune responses. Moreover, significant therapeutic efficacy of the Ad-B7H1/B7H3 vaccine was observed in lung metastasis, orthotopic, and humanized tumor models through multifunctional CD8⁺ T cell immune responses.

The Ad vaccine targeting dual immune checkpoints B7H1 and B7H3 exerts a potent therapeutic effect for renal carcinoma and holds promise for solid tumor treatment.